Archive for the ‘Gene Therapy Research’ Category

Overview Of Primary Cell Culture Industry 2020-2026:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Primary Cell Culture Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Primary Cell Culture Market competition by top manufacturers as follow: , ATCC, Cell Biologics, CellSystems GmbH, Corning, Creative Bioarray, FUJIFILM Irvine Scientific, GE Healthcare, Irvine Scientific, Lonza, MatTek Ltd, Merck, Promocell GmbH, Themo Scientific

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/9633

The global Primary Cell Culture market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: Explant MethodEnzymatic DisaggregationMechanical SeparationOther

Market Segment by Applications, covers:Tissue Culture & Tissue EngineeringVaccine ProductionGene Therapy and Regenerative MedicineToxicity Testing and Drug ScreeningCancer ResearchPrenatal DiagnosisStem Cell TherapyOther

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/9633

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Primary-Cell-Culture-Market-9633

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See more here:
COVID-19 Impact: Primary Cell Culture Market | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth Analysis by...

Global Cell Phone Wireless Chargers Market OverviewGlobal Cell Phone Wireless Chargers Market presents insights on the current and future industry trends, enabling the readers to identify the products and services, hence driving the revenue growth and profitability. The research report provides a detailed analysis of all the major factors impacting the market on a global and regional scale, including drivers, constraints, threats, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

Understand the influence of COVID-19 on the Cell Phone Wireless Chargers Market Size with our analysts monitoring the situation across the globe.

The novel COVID-19 pandemic has put the world on a standstill, affecting major operations, leading to an industrial catastrophe. This report presented by Garner Insights contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak..

Access PDF Sample Copy of the Report, With 30 mins free consultation! Click [emailprotected]https://garnerinsights.com/Cell-Phone-Wireless-Chargers-Market-Research-Global-StatusForecast-by-Geography-TypeApplication-2016-2026#request-sample

This Cell Phone Wireless Chargers market report aims to provide all the participants and the vendors will all the details about growth factors, shortcomings, threats, and the profitable opportunities that the market will present in the near future. The report also features the revenue share, industry size, production volume, and consumption in order to gain insights about the politics to contest for gaining control of a large portion of the market share.

Top Key Players in the Cell Phone Wireless Chargers Market: , Samsung, Google, USAMS, Sony, Aigo, Motorola, HTC, LG,,.

Competitive landscapeThe Cell Phone Wireless Chargers Industry is severely competitive and fragmented due to the existence of various established players taking part in different marketing strategies to increase their market share. The vendors operating in the market are profiled based on price, quality, brand, product differentiation, and product portfolio. The vendors are turning their focus increasingly on product customization through customer interaction.Cell Phone Wireless Chargers Market segment by Regions/Countries: United States, Europe, China, Japan, Southeast Asia, India, Central & South America.

To get this report at a profitable rate.: https://garnerinsights.com/Cell-Phone-Wireless-Chargers-Market-Research-Global-StatusForecast-by-Geography-TypeApplication-2016-2026#discount

Major Types of Cell Phone Wireless Chargers covered are:, Electromagnetic Induction Way, Magnetic Resonance (NMR) Method, Electromagnetic Coupling Way, Microwave Resonant Mode,,

Major end-user applications for Cell Phone Wireless Chargers market:, Homehold, Public Places,,

Points Covered in The Report:

Reasons for Buying Global Cell Phone Wireless Chargers Market Report:

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.garnerinsights.com/Cell-Phone-Wireless-Chargers-Market-Research-Global-StatusForecast-by-Geography-TypeApplication-2016-2026

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, Europe.

Contact Us:Kevin ThomasContact No: +1 513 549 5911 (US)+44 203 318 2846 (UK)[emailprotected]

Read the original post:
Impact of Covid-19 on Cell Phone Wireless Chargers Market 2020 | Latest trending industry is booming globally by Top key Samsung, Google, USAMS -...

The new research report titled Cell Culture Market published by Global Marketers into his huge database. Primary and secondary research methodologies have been used to formulate this report. This Report Provides an in-depth study analyzing the current and future demands of this market also it provides the overview, definition, cost structure, segmentation, recent developments, application,and industry chain analysis, CAGR growth, and Porters Five Forces Analysis, demand. The report has offered an all-inclusive analysis of the global market taking into consideration all the pivotal aspects like growth factors, market developments, future prospects, and trends.

Get/Download Free sample report, @ https://www.globalmarketers.biz/report/life-sciences/2014-2029-report-on-global-cell-culture-market-by-player,-region,-type,-application-and-sales-channel/152702 #request_sample

Thermo FisherMerck MilliporeCorningGE HealthcareBDTakaraLonzaHiMediaCellGenixPromoCell

This Cell Culture market report will help you determine and analyze your portfolio of key market players with information such as company profile, components and services offered, financial information from the past three years, and key developments it helps you to develop a strategy to gain a competitive edge in the past 4-5 years.

North America (United States, Canada), Asia-Pacific (China, Japan, India, Australia, and South Korea), Latin America (Brazil, Mexico, etc.), The Middle East and Africa (GCC and South Africa), Europe (Germany, Spain, France, UK, Russia, and Italy)

The competitive landscape of the Cell Culture Market is discussed in the report, including the market share and new orders market share by the company. The report profiles the leading players in the market for providing an in-depth study of this industry as well as provides growth opportunities, future demands of this market. The report also discusses the implemented by the key vendors to maintain their hold on the industry. The business overview and financial overview of each of the key vendors have been analyzed in this research Report.

The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period. This report defines the current and present situation as well as the future forecast of this Cell Culture Market. Also, this report provide all the information on Impact Analysis of COVID-19 on this industry.

Cell Culture Market By Type:

Classical Media & SaltsSerum-free MediaStem Cell MediaOthers

Cell Culture Market By Application:

Biopharmaceutical ManufacturingTissue Culture & EngineeringGene TherapyOther

Hurry Up!!! Ask For Discount https://www.globalmarketers.biz/discount_inquiry/discount/152702

For more Information or Browse the complete report @ https://www.globalmarketers.biz/report/life-sciences/2014-2029-report-on-global-cell-culture-market-by-player,-region,-type,-application-and-sales-channel/152702 #table_of_contents

Read the original:
Global Cell Culture Market Size, Share, Growth Drivers, Regional Analysis and forecasts to 2029 - 3rd Watch News

Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.

The technology relies on inserting into cells pieces of carefully designed messenger RNA (mRNA), a strip of genetic material that human cells typically transcribe from a persons DNA in order to make useful proteins and go about their business. Problems delivering mRNA safely and intact without running afoul of the immune system have held back mRNA-based therapy, but UWMadison researchers are making tiny balls of minerals that appear to do the trick in mice.

These microparticles have pores on their surface that are on the nanometer scale that allow them to pick up and carry molecules like proteins or messenger RNA, saysWilliam Murphy, a UWMadison professor of biomedical engineering and orthopedics. They mimic something commonly seen in archaeology, when we find intact protein or DNA on a bone sample or an eggshell from thousands of years ago. The mineral components helped to stabilize those molecules for all that time.

Murphy and UWMadison collaborators used the mineral-coated microparticles (MCMs) which are 5 to 10 micrometers in diameter, about the size of a human cell in a series of experiments to deliver mRNA to cells surrounding wounds in diabetic mice. Wounds healed faster in MCM-treated mice, and cells in related experiments showed much more efficient pickup of the mRNA molecules than other delivery methods.

The researchers described their findings today in the journal Science Advances.In a healthy cell, DNA is transcribed into mRNA, and mRNA serves as the instructions the cells machinery uses to make proteins. A strip of mRNA created in a lab can be substituted into the process to tell a cell to make something new. If that something is a certain kind of antigen, a molecule that alerts the immune system to the presence of a potentially harmful virus, the mRNA has done the job of a vaccine.

The UWMadison researchers coded mRNA with instructions directing cell ribosomes to pump out a growth factor, a protein that prompts healing processes that are otherwise slow to unfold or nonexistent in the diabetic mice (and many severely diabetic people).

mRNA is short-lived in the body, though, so to deliver enough to cells typically means administering large and frequent doses in which the mRNA strands are carried by containers made of molecules called cationic polymers.

Oftentimes the cationic component is toxic. The more mRNA you deliver, the more therapeutic effect you get, but the more likely it is that youre going to see toxic effect, too. So, its a trade-off, Murphy says. What we found is when we deliver from the MCMs, we dont see that toxicity. And because MCM delivery protects the mRNA from degrading, you can get more mRNA where you want it while mitigating the toxic effects.

The new study also paired mRNA with an immune-system-inhibiting protein, to make sure the target cells didnt pick the mRNA out as a foreign object and destroy or eject it.

Successful mRNA delivery usually keeps a cell working on new instructions for about 24 hours, and the molecules they produce disperse throughout the body. Thats enough for vaccines and the antigens they produce. To keep lengthy processes like growing replacement tissue to heal skin or organs, the proteins or growth factors produced by the cells need to hang around for much longer.

What weve seen with the MCMs is, once the cells take up the mRNA and start making protein, that protein will bind right back within the MCM particle, Murphy says. Then it gets released over the course of weeks. Were basically taking something that would normally last maybe hours or even a day, and were making it last for a long time.

And because the MCMs are large enough that they dont enter the bloodstream and float away, they stay right where they are needed to keep releasing helpful therapy. In the mice, that therapeutic activity kept going for more than 20 days.

They are made of minerals similar to tooth enamel and bone, but designed to be reabsorbed by the body when theyre not useful anymore, says Murphy, whose work is supported by the Environmental Protection Agency, the National Institutes of Health and the National Science Foundation and a donation from UWMadison alums Michael and Mary Sue Shannon.

We can control their lifespan by adjusting the way theyre made, so they dissolve harmlessly when we want.

The technology behind the microparticles was patented with the help of the Wisconsin Alumni Research Foundation and is licensed to Dianomi Therapeutics, a company Murphy co-founded.

The researchers are now working on growing bone and cartilage and repairing spinal cord injuries with mRNA delivered by MCMs.

Reference: Khalil et al. (2020).Single-dose mRNA therapy via biomaterial-mediated sequestration of overexpressed proteins. Science Advances.DOI: 10.1126/sciadv.aba2422.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to read the rest:
Safer and More Efficient Method To Deliver Gene Therapy - Technology Networks

Global Gene Therapy Market Research report 2020 provides overview including size, share, industry growth, product scope, development plans, region trends, consumptions, demand factors, types and application, and value chain structure. The Global Gene Therapy analysis is also provided for the international markets including market opportunities, investment plans, historical data, and research expert opinions.

Get Sample Copy https://www.orianresearch.com/request-sample/1529811

Development policies, investment plans, cost structures, capacity are discussed as well as growth rate, manufacturing processes, economic growth are analyzed. This Gene Therapy research report also states import/export data, industry supply and consumption figures as well as cost structure, price, industry revenue (Million USD) and gross margin by regions like (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China etc.)

The major players profiled in this report include:

Inquire more or share questions if any before the purchase on this report https://www.orianresearch.com/enquiry-before-buying/1529811

Gene Therapy Industry research report is a meticulous investigation of the current scenario of the Gene Therapy global and regional market, which covers several industry dynamics. The Gene Therapy market research report is a resource, which provides current as well as upcoming technical and financial details with market risk, growing demand and raw materials. The thorough analysis in this Gene Therapy report enables investors, CEOs, regional traders, suppliers, top vendors to understand the market in a better way and based on that knowledge make well-informed decisions.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Gene Therapy for each application, including-Medical

Place a Direct Order of this Report https://www.orianresearch.com/checkout/1529811

Gene Therapy Market Report Table of Contents:

Chapter 1 Gene Therapy Market Executive Summary

Chapter 2 Gene Therapy Abbreviation and Acronyms

Chapter 3 Gene Therapy Preface

Chapter 4 Gene Therapy Market Landscape

Chapter 5 Gene Therapy Market Trend Analysis

Chapter 6 Gene Therapy Industry Chain Analysis

Chapter 7 Latest Gene Therapy Market Dynamics

Chapter 8 Gene Therapy Trading Analysis

Chapter 9 Historical and Current Gene Therapy in North America (2014-2019)

Chapter 10 Historical and Current Gene Therapy in South America (2014-2019)

Chapter 11 Historical and Current Gene Therapy in Asia & Pacific (2014-2019)

Chapter 12 Historical and Current Gene Therapy in Europe (2014-2019)

Chapter 13 Historical and Current Gene Therapy in MEA (2014-2019)

Chapter 14 Summary for Global Gene Therapy (2014-2019)

Chapter 15 Global Gene Therapy Forecast (2020-2024)

Chapter 16 Gene Therapy Analysis of Global Key Vendors

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (832) 380-8827 | UK: +44 0161-818-8027

Email: [emailprotected]

The rest is here:
Why Gene Therapy Market Trending in 2020? Know COVID-19 Impact on Growth and Forecast Research till 2024 - Jewish Life News

The latest research report on the Gene Therapy market covering in-depth analysis of size, segmentation market growth, market share, competitive Landscape, Detailed List of Key Buyers and End-Users, Market Attractiveness Analysis, and Key Investment Opportunity Analysis, product launches, area marketplace expanding, and technological innovations.

Leading market research company Facts & Factors (FnF) published a market research report onGene Therapy Market By Type (Germ Line Gene Therapy and Somatic Gene Therapy), By Vector Type (Viral Vectors, Non-Viral Vectors, and Human Artificial Chromosome), and By Therapy Area (Cancer, Neurological Diseases, Infectious Diseases, Genetic Disorders, Rheumatoid Arthritis, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 2027includes 190+ pages research PDF with TOC including a list of table and figures in its research offerings.

TheGene Therapy marketreport analyses and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire Gene Therapy market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Billion) from FY 2016 2026.

The Gene Therapy market 2020-2026 report includes market size, segmentation, growth, trends, opportunities, and challenges. The Gene Therapy market includes factors driving industry growth and opportunities. Gene Therapy market size & share report evaluates current market scenario, insights, and updates about the corresponding segments involved in the global and regional market for the forecast period of 2020-2026. The Gene Therapy market research includes historical and forecasts market data, demand, application details, price trends, and company shares of the leading Gene Therapy by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

Request an Exclusive Free Sample Report of Gene Therapy Market:https://www.fnfresearch.com/sample/gene-therapy-market-by-type-germ-line-gene

(The sample of this report is readily available on request).

Benefits of Requesting a FREE Sample Report Before Purchase:

(Note: The sample of this report is updated with COVID-19 analysis before delivery)

Some of Following Top Market Players Profile Included in This Report:

Gene Therapy Market Analysis by Leading Market Players

Leading top market players in the Gene Therapy market are analyzed in the report along with their business overview, operations, geographical locations, financial analysis, SWOT profile, and Gene Therapy products & services.

COVID-19- Current Scenario, Potential Impact, and Strategic Situation Analysis

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

COVID-19 is turning into a pandemic. Prepare your organization for the changes beginning to take place. Develop an understanding of the risks and probabilities and learn how your industry and your nation will be affected.

Enquire About COVID-19 Updates for This Report:https://www.fnfresearch.com/inquiry/gene-therapy-market-by-type-germ-line-gene

Report Analysis Overview:

The report includes an elaborate executive summary along with a snapshot of the growth behavior of various segments in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the Gene Therapy market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the Gene Therapy market.

The report delves into the competitive landscape of the Gene Therapy market. Key players operating in the global Gene Therapy market are identified and each one of these is profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT analysis are some of the attributes of players in the Gene Therapy market profiled in this report.

Request Customized Copy of Report @https://www.fnfresearch.com/customization/gene-therapy-market-by-type-germ-line-gene

(We customize your report according to your research need. Ask our sales team for report customization.)

Free Customization

This report includes Free Customization which generally involves a breakout of particular industries or country data at no additional charge. An analyst call can be arranged as part of this which is included in the free customization offering. The Gene Therapy Market can be customized to the country level or any other market segment. Besides this, the report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

Spreadsheet Chapters include

Market Consumption in US$ by Country by Product/Service by Year. Market, Financial, Competitive, Market Segmentation, Industry, Critical Parameters, Marketing Costs, Markets, Decision Makers, Performance, Product Launch.

Read More Report Details Here:https://www.fnfresearch.com/gene-therapy-market-by-type-germ-line-gene

The Report Covers

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

A 2108, Sargam,

Nanded City,

Sinhagad Road,

Pune 411041, India

USA: +1-347-989-3985

E-Mail:[emailprotected]

Web:https://www.fnfresearch.com

Continued here:
Size & Trends of Gene Therapy Market Research Report 2020 Updated With COVID-19 Analysis and Forecast till 2026 - Jewish Life News

Integrated Health System is bringing cell and gene therapy to cats, dogs, and horses. Recently IHS Pets has helped a paralyzed dog with a spinal cord injury to walk again after it was treated with experimental PRP and prolotherapy. Click here to see the video.

Telomeres

Aging is the root of virtually every complex noncommunicable disease in humans and animals. Telomeres are the protective end caps on the ends of our chromosomes, they are as important for the health of both humans and our pets, and they play roles in longevity.

One of the contributing factors in the lifespan in dog breeds is telomere length. As in humans researchers have found that telomere length is a strong predictor of average life span among 15 different breeds consistent with telomeres playing a role in life span determination. Dogs lose telomeric DNA ~10-fold faster than humans, which is similar to the ratio of average life spans between these species. As such telomerase therapy may be beneficial to pets as well as their human caretakers.

Telomerase gene therapy has been shown to extend lifespan in animals, this therapy may help to increase bone mineral density, improve motor performance, improve metabolism, and improve brain function.

Follistatin

The loss of muscle mass with age is just as problematic for animals as it is to humans; in cats for instance a study showed that for each 100g loss of lean body mass increased the risk of death by 20%. This is typically accompanied by frailty, and it is a contributing factor to metabolic syndrome, diabetes, heart disease, and overall mortality.

Diet and exercise have been shown to pay key roles in keeping pets healthy, but the loss of muscle mass is unavoidable without an effective intervention. Enter follistatin: myostatin blocks muscle growth, when it is inhibited then follistatin is able to let muscles grow freely to stop them from wasting away.

Follistatin gene therapy has been shown to be safe and effective in animals, this therapy may help to protect against frailty, increase muscle density, increase strength, and increase endurance.

Klotho: The Queen of Anti-Aging Proteins

1 in 3 cats will suffer from renal disease, but these numbers are under scrutiny with some suggesting that estimate may be too conservative. Chronic kidney failure can occur gradually over months or years, and it is one of the most common conditions affecting older cats with most cases progressing over time worsening the disease.

Klotho is known to play a significant role in the development of chronic kidney disease, and researchers are now turning to its broader role in the anging process as a whole; such as induces expression with gene therapy in mice has been shown to extend lifespan by targeting many of the same pathways as caloric restriction. Blocking Klotho has been shown to cause premature aging.

Klotho also helps to protect the brain, and contributes to more differences in intelligence than any one single gene. Research from the University of California has shown it to protect the brains of mice and improve brain function within 4 hours; and this result included young mice, old mice, and those that were models of Alzheimers disease.

In addition Klotho also plays a critical role in the inflammaging process. Inflammaging is the long term result of the chronic physiological stimulation of the innate immune system which can become damaging during the aging process.

Circulating levels of Kloto decreases with age, this decrease is associated with an increased risk of age related disease. Gene therapy with Klotho has been shown to increase lifespan in animal models, and it may improve kidney function, brain function, clear damage caused by oxidative stress, and protect against cardiovascular disease.

With the remarkable progress being made in genetics, gene therapy may play increasingly prominent and transformative roles in medicine for both humans and animals due to the potential to treat diseases and congenital disorders.

Pets can be an important part of life, they calm us, make us laugh, and create a bond of unconditional love. The company does note that all therapies are experimental, they are not approved by any regulatory body, and they make no claims that outcomes will be positive or beneficial.

IHS Pets is the veterinary wing of Integrated Health Systems, BioViva Sciences exclusive partner. IHS connects with doctors and patients who are interested in the power of gene therapy to pave the way to healthy aging and longevity.

Read more here:
IHS Pets: Bringing Cell And Gene Therapy To Cats, Dogs & Horses - Anti Aging News

Biogen has picked up a new, preclinical gene therapy program from Massachusetts Eye and Ear for inherited retinal degeneration due to mutations in the PRPF31 gene, among the most common causes for autosomal dominant retinitis pigmentosa. Theyre building on the work of Harvards Eric Pierce. The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, the research head at Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD.

Sarepta has inked a collaboration with Hansa to develop their experimental drug imlifidase as a pre-treatment for their gene therapies. The drug is intended for use in patients who have neutralizing antibodies that would prevent gene therapies for Duchenne muscular dystrophy and Limb-girdle muscular dystrophy from working. Hansa gets a $10 million upfront and up to $397.5 million in milestones.

Its been raining money on Wall Street at least when it comes to drug developers. CRISPR Therapeutics $CRSP and Acceleron each raised a whopping $450 million this week after pricing follow-on offerings. CRISPR priced 6,428,572 common shares at a public offering price of $70.00 per share, while Acceleron $XLRN auctioned off 4,864,864 shares of common stock at a price to the public of $92.50 per share.

The transatlantic biotech player Immatics has completed its flip onto Nasdaq through the Arya Sciences Acquisition Corp. The cancer drug biotech will trade as $IMTX after it raised $253 million in the process. The SPAC was set up by Perceptive Advisors.

Seattle-based Neoleukin Therapeutics, meanwhile, raised $76.2 million $NLTX for its work on protein therapeutics.

The rest is here:
Biogen bags an AAV gene therapy program from Massachusetts Eye and Ear; Biotechs raised $1B-plus in latest round of follow-ons - Endpoints News

Hansa grants Sarepta exclusive license to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy in Duchenne muscular dystrophy and Limb-girdle muscular dystrophy, for patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV).

Under the terms of the license: Hansa will receive a USD 10 million upfront payment and is eligible for up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase and would be eligible for royalties in the high single-digits to mid-teens on any gene therapy sales enabled through pre-treatment with imlifidase in NAb-positive patients.

Lund, Sweden July 2, 2020. Hansa Biopharma (Hansa), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced today that it has entered into an agreement with Sarepta Therapeutics Inc. (Sarepta), the leader in precision genetic medicine for rare diseases, through which Sarepta is granted an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD). The pre-treatment is intended for patients with pre-existing neutralizing antibodies (NAb-positive patients) to adeno-associated virus (AAV), the technology that is the basis for Sareptas gene therapy products.

Sarepta will be responsible for conducting pre-clinical and clinical studies with imlifidase and any subsequent regulatory approvals. Sarepta will also be responsible for the promotion of imlifidase as a pre-treatment to Sareptas gene therapies following potential approval.

Under the terms of the agreement, Hansa will receive a USD 10 million upfront payment, and is eligible for a total of up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase, and earn high single-digit to mid-teens royalties on Sareptas incremental gene therapy sales when treating NAb-positive patients enabled through pre-treatment with imlifidase.

Sren Tulstrup, President & CEO of Hansa Biopharma comments,We see significant potential for our enzyme technology in the gene therapy space overall, and we are excited to partner with Sarepta, a leading player in the field, to use the unique features of imlifidase to potentially enable gene therapy treatment in patients who today arent eligible for these breakthrough therapies due to pre-existing neutralizing antibodies in two conditionswith a very high unmet medical need.

Doug Ingram, President & CEO, Sarepta Therapeutics said,As we expand our leadership position in genetic medicine and build out our gene therapy engine, one of Sareptas central ambitions is to find scientific solutions that bring our potentially life-saving therapies to the greatest number of the rare disease patients we serve. One of the current limitations of gene therapy is the inability to treat patients who have pre-existing neutralizing antibodies to the AAV vector. While our AAVrh74 vector has been associated with a low screen out rate for neutralizing antibodies, even that low rate is inconsistent with our mission.

In pre-clinical and clinical models, Hansas technology has shown the ability to clear the IgG antibodies that prevent dosing AAV-based gene therapies. If successful, this could offer the potential of extending our gene therapy treatments to DMD and LGMD patients who would otherwise have been denied access due to pre-existing antibodies.

Hansa Biopharma will be hosting a conference call with President & CEO Sren Tulstrup, CSO & COO Christian Kjellman and CFO Donato Spota.

Conference Call Partnership agreement with Sarepta TherapeuticsA conference call will take place July 2nd, 2020 at 10:00am CET. The audio cast will be recorded and subsequently be available on the Hansa website https://hansa.eventcdn.net/202007

Participants dial-in numbersSE: + 46 81 241 09 52UK: + 44 203 769 6819US: + 1 646 787 0157

This is information that HansaBiopharma AB is obliged to makepublic pursuant to the EU MarketAbuse Regulation.

About imlifidaseImlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response. It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020.Hansa has also reached an agreement with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S. and has three ongoing phase 2 trials in autoimmune diseases and post-transplant indications.

About gene therapy and neutralizing antibodiesGene therapy is a growing and revolutionizing treatment technology in which healthy gene sequences are inserted into cells of a patient. The treatments are potentially curative in monogenic diseases like hemophilia and muscular dystrophy through a single dose. Harmless recombinant viruses are used to carry the healthy genes into the cell. Due to the partial viral origin of the gene therapy constructs, a certain subset of patients carry neutralizing anti-AAV antibodies towards gene therapy products, depending on what AAV serotype being used, forming a barrier for treatment eligibility.Antibodies prevent effective transfer of healthy gene sequence and can be a safety concern. Imlifidase as a pre-treatment may have the potential to eliminate neutralizing antibodies prior to gene therapy. Similarly, imlifidase may have the potential to enable any potentially necessary re-dosing of gene therapy for all patients.

About Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy is a rare genetic disease caused by mutation in the DMD gene, encoding for the protein dystrophin. Duchenne is an irreversible, progressive disease that causes the muscles in the body to become weak and damaged over time. It is eventually fatal and there is no cure. DMD affects one in 3,500 to 5,000 males born worldwide (approximately 400-500 annual cases in the US) and causes muscles in the body to become weak and most patients use wheelchair by the age of 12.

About Limb-Girdle Muscular Dystrophy (LGMD)Limb-girdle muscular dystrophy or (LGMD) is a genetically and clinically heterogeneous group of rare muscular dystrophies. It is characterised by progressive muscle wasting which affects predominantly hip and shoulder muscles. LGMD has an autosomal pattern of inheritance and currently has no known cure or treatment. It can be caused by a single gene defect that affects specific proteins within the muscle cell, including those responsible for keeping the muscle membrane intact. LGMD has a global prevalence of approximately 1.63 per 100,000 individuals worldwide.

For further information, please contact:Klaus Sindahl, Head of Investor RelationsHansa Biopharma Mobile: +46 (0) 709-298 269E-mail: klaus.sindahl@hansabiopharma.com

About Hansa BiopharmaHansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.The Companys lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansas research and development program is advancing the next generation of the Companys technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

View original post here:
Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se...

The report covers the forecast and analysis of the Cell and Gene Therapy Consumables market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the Cell and Gene Therapy Consumables market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Cell and Gene Therapy Consumables market on a global level.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10172657

In order to give the users of this report a comprehensive view of the Cell and Gene Therapy Consumables market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service & product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the Cell and Gene Therapy Consumables market by segmenting the market based on product type, application/therapeutics, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

A rise in the awareness about the gene & cell therapies will propel the market growth during the period from 2019 to 2027. Nevertheless, conducting randomized control tests will inhibit the expansion of the market during the forecast timeline. However, the growing trend for treating neurodegenerative ailments through the use of gene treatment will proliferate the market growth over the forecast period.

The expansion of the market during the forecast timespan is owing to the high frequency of chronic ailments including cancer and heart disorders. Apart from this, inflation in the occurrence of these disorders produces lucrative demand for enhanced therapies and this will culminate in the market demand over the forecast time span.

Request For Full Report:https://www.kennethresearch.com/sample-request-10172657

Based on the product type, the market is sectored into Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media. Application/ Therapeutics- wise, the market for cell and gene therapy consumables are classified into Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology.

Some of the key players in the market include Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook, Dendreon Pharmaceuticals, LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc., Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, Helixmith Co., Ltd., and Vitrolife.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

Original post:
Cell And Gene Therapy Consumables Market Size, Share And Top Key Players During 2020-2027 Bulletin Line - Bulletin Line

The government unveiled its plans to invest 2.8 trillion won ($2.3 billion) in developing new key technologies to foster the bio-health industry over the next decade.

The Ministries of Health and Welfare, Science and ICT, and Trade, Industry and Energy said on Friday that two interagency projects -- new drug development and regenerative medicine technology development -- had passed the preliminary feasibility study last month.

The two national projects are part of the Bio-Health Industry Innovation Strategy announced by the government in May last year.

In pursuing new drug development as a state project, the government will provide step-by-step support, starting from basic research, going through nonclinical and clinical trials, and reaching test manufacture and mass production.

According to the viability study, the project will likely create 2.1 trillion won in industrial production for 10 years from 2021, to emerge as the largest R&D project to be conducted by the Ministry of Health and Welfare.

The three ministries said they plan to support the project by abolishing barriers as if they were one ministry. To this end, they have established a unified administrative system for the project by building up their capabilities, providing integrated consultation and support customized to the needs of universities, research institutions, and businesses.

Through the project, the government aims to develop blockbuster new drugs, each with annual sales of more than 1 trillion won ($830 million) over the next decade while enhancing the pharmaceutical industry's competitiveness.

Concerning the development of regenerative medicine technology, the government will provide support throughout the period, from the core basics and the original technology to the clinical stage of therapeutic and therapeutic technologies for regenerative medicines.

The field of regenerative medicine, despite expectations as a future medical technology, has experienced limitations in developing new technologies because of the legal system.

After the National Assembly passed the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals last year, research and development conditions and ecosystems for the regenerative medicine field have made marked improvement.

Encouraged by the brighter prospect, the government has decided to invest 595.5 billion won in this area for 10 years from 2021.

It plans to focus on strengthening the technological competitiveness of stem cell therapy products and core technologies with high potential for future growth, such as gene therapy and tissue engineering materials.

"Through the development of the bio-health industry, we will develop innovative new drugs to treat rare, incurable diseases, protect health sovereignty through localization of pharmaceuticals and medical technologies, and strengthen public health," said Im In-taek, director-general of the Health Industry Policy Bureau in the health and welfare affairs ministry.

Based on the results of the recent preliminary feasibility study, the three related ministries will go all out for the project's success, Im added.

corea022@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

Originally posted here:
Korea to invest 2.8 trillion in promoting bio-health sector - Korea Biomedical Review

No matter how many molecules he threw at them, Paul Tesar couldnt get the brain cells to survive. Or he got them to survive, but then to everyones bafflement they still couldnt do what they were supposed to.

Tesar, a professor of innovative therapeutics at Case Western University, had spent years building stem cell models for multiple sclerosis, growing brain organoids in dishes and then seeing what small molecules restored myelin production. Now he was trying to do the same for other myelin diseases, particularly an ultra-rare genetic condition called Pelizaeus-Merzbacher disease, where a single mutation leads to the death of the myelin-producing neurons, called oligodendrocytes, and can kill patients in infancy.

Weve screened many thousands of small molecule compounds, Tesar toldEndpoints News. But we could not get them to restore function.

Then Tesar got an email from Ionis, the California biotech that had just used an RNA-modifying technology called antisense to build Spinraza, the first FDA-approved drug for the genetic neurological disorder spinal muscular atrophy.

Now, in a study published inNature,Tesar and Ionis have shown they can use a single dose of drug built from that technology to keep those neurons both alive and well-functioning and treat the disease at least in mice. The publication isnt groundbreaking, antisense researchers say, but it shows for the first time that antisense can be used to effectively target oligodendrocytes, an insight its authors hope will open up other rare myelin disorders to therapy.

Its not that its different than everything thats been done before, but it goes further than everything thats gone before, Jon Watts, a professor at the RNA Therapeutics Institute at UMass Medical School who is not affiliated with Ionis or the paper, told Endpoints, both in terms of duration of effect after a single dose, and the real focus in getting the biology, the therapeutic effect in oligodendrocytes.

The applicability to the most famous and common of myelin disorders, multiple sclerosis, is limited, researchers say, both because the therapy relied on having a specific gene to target and because the paper doesnt prove you can get an effect on the peripheral nervous system. Still, Berit Powers, an assistant director at Ioniss neurology research department and a co-author, pointed to several other genetic myelin disorders, known as leukodystrophies. That includes an Ionis program on Alexander disease, a rare childhood condition with Parkinsons-like symptoms.

Were certainly exploring the potential of ASOs in non-monogenic conditions like MS, Powers told Endpoints, using a shorthand for antisense oligonucleotides. But that work is very new.

This is hardly Tesars first foray into biotech. In 2015, he showed in Naturehow certain small molecules could regenerate myelin the holy grail for an MS therapy and founded Convelo Therapeutics around that work. Last year, they partnered with Genentech for an undisclosed sum and an exclusive option to acquire the company.

Myelin is a fatty substance that coats neurons, insulating them and helping electric currents pass through. Tesars lab was broadly interested in the question of why myelin fails, both in MS and rare diseases, and about 7 years ago he got a grant to work from the PMD Foundation.

First, Tesar built stem cell models of the disease, figuring out how different mutations in a single gene, called PLP1, lead oligodendrocyte progenitor cells (the stem cell-like cells that will become oligodendrocytes) to create a toxic RNA and a mutated protein that kills them soon after they differentiate. Then, he tried to suppress that gene with different chemicals, eventually testing over 3,000 different compounds.

He was able to eventually get the oligodendrocytes to survive, but to his surprise, they didnt produce myelin as they should. The surviving cells still couldnt properly function, revealing, he wrote in a 2018 Cell paper a second phase of pathology. A hypothetical treatment, he argued, would have to both keep progenitor cells alive and then treat the survivors in a way that induces myelination.

With antisense, he and Powers Ionis team were able to do both. Antisense oligonucelotides consist of strands of RNA that are a mirror image of the RNA you want to target. The mirror binds to and silences, or turns off, that gene. In the study, the researchers confirmed that PLP1 was disease-causing by knocking out the gene in cell lines with CRISPR. Then they injected mice with antisense strands through the spinal cord, the same way Spinraza is delivered. (You cant use CRISPR to treat the disease in humans, because theres no good way yet of delivering it.)

Powers and Tesar were unsure if they would be able to target oligodendrocytes and progenitor cells. What they found, though, was complete restoration of oligodendrocytes and a profound rescue of neurological function. Myelin, too, was finally restored. Mice that died after 3 weeks now lived for over 200 days.

Ionis hasnt licensed the drug and its unclear yet the implications for other diseases, but researchers say the results could translate into humans quickly, at least by drug development standards.

I do think its very rapidly translatable, Watts said. Based on the data theyre showing here, and based on the unmet need, this appears to be something that could be translated pretty quickly into a Phase I trial.

The rest is here:
Ionis, leading MS researcher throw antisense at a new type of brain cells - Endpoints News

New York, July 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Brain Tumor Therapeutics Market Research Report by Type, by Therapy - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913675/?utm_source=GNW

On the basis of Type, the Brain Tumor Therapeutics Market is studied across Glioblastoma, Meningioma, and Pituitary Tumors.

On the basis of Therapy, the Brain Tumor Therapeutics Market is studied across Gene Therapy, Immunotherapy, and Tissue Engineering.

On the basis of Geography, the Brain Tumor Therapeutics Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Brain Tumor Therapeutics Market including GlaxoSmithKline PLC, Johnson & Johnson, AstraZeneca PLC, Bristol-Myers Squibb Co, Pfizer Inc., Amgen Inc., Bayer AG, Eisai Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., and Novartis AG.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Brain Tumor Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Brain Tumor Therapeutics Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Tumor Therapeutics Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Tumor Therapeutics Market?4. What is the competitive strategic window for opportunities in the Global Brain Tumor Therapeutics Market?5. What are the technology trends and regulatory frameworks in the Global Brain Tumor Therapeutics Market?6. What are the modes and strategic moves considered suitable for entering the Global Brain Tumor Therapeutics Market?Read the full report: https://www.reportlinker.com/p05913675/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More here:
The Global Brain Tumor Therapeutics Market is expected to grow from USD 2,252.58 Million in 2019 to USD 3,420.14 Million by the end of 2025 at a...

The Ample Market Research Added A new industry research report that focuses on Cancer Gene Therapy Market and delivers in-depth market analysis and future outlook of Cancer Gene Therapy market. The study covers significant data which makes the research report a handy resource for managers, analysts, industry experts, and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges.

This is the latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions.

The report begins with a brief introduction and market overview of the Cancer Gene Therapy industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed, along with current trends and policies in the industry.

Latest Sample Copy of this Cancer Gene Therapy Market Report:https://www.amplemarketreports.com/sample-request/global-cancer-gene-therapy-market-1770310.html

The report offers an extensive analysis of key drivers, leading market players, key segments, and regions. Besides this, the experts have deeply studied different geographical areas and presented a competitive scenario to assist new entrants, leading market players, and investors to determine emerging economies. These insights offered in the report would benefit market players to formulate strategies for the future and gain a strong position in the global market.

The key players profiled in this report include: Adaptimmune, Bluebird bio, Celgene, Shanghai Sunway Biotech, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Altor BioScience, Amgen, Argenx, BioCancell, GlaxoSmithKline, Merck, OncoGenex Pharmaceuticals, Transgene

The key product type of Cancer Gene Therapy market are: Oncolytic Virotherapy, Gene Transfer, Gene-Induced Immunotherapy

The end users/applications listed in the report are: Hospitals, Diagnostics Centers, Research Institutes

The report provides a detailed study of the growth rate of every segment with the help of charts and tables. Furthermore, various regions related to the growth of the market are analyzed in the report.

These regions include: North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC)

Analysts have revealed that the Cancer Gene Therapy market has shown several significant developments over the past few years. The report offers sound predictions on market value and volume that can be beneficial for the market players, investors, stakeholders, and new entrants to gain detailed insights and obtain a leading position in the market.

Get Complete Report in your Inbox within 24 hours Now at : https://www.amplemarketreports.com/buy-report.html?report=1770310&format=1

The research presents the performance of each player active in the Cancer Gene Therapy market. It also offers a summary and highlights the current advancements of each player in the market. This piece of data is a great source of study material for the investors and stakeholders interested in the market. In addition, the report offers insights on suppliers, buyers, and merchants in the market. Along with this, a comprehensive analysis of consumption, market share, and growth rate of each application is offered for the historic period.

Cancer Gene Therapy market Following Details Segment by Table of Contents:

1 Cancer Gene Therapy market Overview

2 Manufacturers Profiles

3 Cancer Gene Therapy Market Competition, by Players

4 Cancer Gene Therapy Market Size by Regions

5 North America Cancer Gene Therapy Revenue by Countries

6 Europe Cancer Gene Therapy Revenue by Countries

7 Asia-Pacific Cancer Gene Therapy Revenue by Countries

8 South America Cancer Gene Therapy Revenue by Countries

9 The Middle East and Africa Cancer Gene Therapy Press by Countries

10 Cancer Gene Therapy market Segment by Type

11 Cancer Gene Therapy Market Segment by Application

12 Cancer Gene Therapy Market Size Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

Request a discount on standard prices of this premium research: https://www.amplemarketreports.com/discount-request/global-cancer-gene-therapy-market-1770310.html

You can also get individual chapter wise section or region wise report versions like North America, Europe or Asia or Country like US, UK, China and other.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to deliver reports that have the perfect concoction of useful data.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

Website: http://www.amplemarketreports.com

Follow this link:
Cancer Gene Therapy Market Will Generate Massive Revenue In Future - A Comprehensive Study On Key Players Adaptimmune, Bluebird bio, Celgene, Shanghai...

The global Genetic Modification Therapies market is expected to exceed more than US$ 3.5 Billion by 2024 at a CAGR of 34% in the given forecast period.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Browse Full Report: https://www.marketresearchengine.com/genetic-modification-therapies-market

The global Genetic Modification Therapies market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Genetic Modification Therapies market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Genetic modification therapies, significantly gene therapy and RNA therapy, have existed for many years, with very little clinical success. However, recent enhancements in these therapies, together with higher delivery systems, additional economical and sturdy gene expression constructs, precise polymer editing tools, have brought this industry to the forefront, and its currently poised for explosive growth within the coming back years.

Because of the potentially curative nature of those medicines theres monumental potential in several applications, starting from cancer to neurology to rare diseases. Genetic modification therapies represent consecutive wave of medicines with monumental potential for treating and curing draining and high diseases. As a result of its wide scope, genetic modification therapy can play a vital role within the future world medical economy.

Continuing advances in key technologies like DNA editing, viral design and production, and gene expression, further as a pressing medical want in several serious and enervating disorders, are driving the expansion of the marketplace for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies trade and build distinctive market opportunities.

The overall market is anticipated to witness important growth in opportunities for a spread of stakeholders within the returning decade. its necessary to spotlight that many technology suppliers, reaching to develop and / or support the event of gene therapies, with improved effectiveness and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation during this domain has additionally semiconductor diode to the invention of novel molecular targets and strong the analysis pipelines of corporations targeted during this house. the potential to focus on numerous therapeutic areas is taken into account to be amongst the foremost outstanding growth drivers of this market.

Market Insights

The global Genetic Modification Therapies market is segregated on the basis of Platform Technology as Gene editing, Gene Therapies, Genetically Modified Cell Therapies, and RNA Therapies. Based on Delivery Technologies the global Genetic Modification Therapies market is segmented in AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral, and Nonviral Based on End-User Industry the global Genetic Modification Therapies market is segmented in Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, and Others.

Based on Disease, the global Genetic Modification Therapies market is segmented in Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases, Other Indications.

Competitive Rivalry

4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others are among the major players in the global Genetic Modification Therapies market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Genetic Modification Therapies Market has been segmented as below:

The Genetic Modification Therapies Market is segmented on the lines of Genetic Modification Therapies Market, By Platform Technology, Genetic Modification Therapies Market, By Delivery Technologies, Genetic Modification Therapies Market, By End-User Industry, Genetic Modification Therapies Market, By Disease, Genetic Modification Therapies Market, By Region and Genetic Modification Therapies Market, By Company.

Genetic Modification Therapies Market, By Platform Technology this market is segmented on the basis of Gene editing, Gene Therapies, Genetically Modified Cell Therapies and RNA Therapies. Genetic Modification Therapies Market, By Delivery Technologies this market is segmented on the basis of AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral and Nonviral. Genetic Modification Therapies Market, By End-User Industry this market is segmented on the basis of Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations and Others. Genetic Modification Therapies Market, By Disease this market is segmented on the basis of Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases and Other Indications. Genetic Modification Therapies Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Genetic Modification Therapies Market, By Company this market is segmented on the basis of 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore and Jivana Biotechnology.

The report covers:

Report Scope:

The global Genetic Modification Therapies market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Genetic Modification Therapies market share. Major industry players with significant revenue share include 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/genetic-modification-therapies-market

Table of Contents:

Other Related Market Research Reports:

Guar Gum Market is Forecast to Cross US$ 1.5 Billion by 2024

High Content Screening Market to Grow US$ 1.10 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Here is the original post:
Genetic Modification Therapies Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape,...

Prostate Cancer Therapeutics Market report covers many business strategies such as new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to amplify their footprints in the market. According to this report, the global market is anticipated to see a relatively higher growth rate during the forecast period. The market drivers and restraints have been explained in this industry report using SWOT analysis. The market share of major competitors on global level is also studied in the Prostate Cancer Therapeutics Market report where key areas such as Europe, North America, Asia Pacific and South America are covered in this market research report.

Prostate cancer therapeutics marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to reach a market value of USD 18.71 billion by 2027 while growing at a CAGR of 7.70% in the above-mentioned forecast period. Prostate cancer therapeutics market is growing due to factor such as increasing cases of prostate cancer and cardiovascular diseases.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific, Brazil, Peru, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Kuwait, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Major Market Competitors/Players:Global Prostate Cancer Therapeutics Market

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Increasing awareness among people regarding prostate cancer along with technological advancement in screening and diagnostic tests, rising preferences of healthy living will increased geriatric population will enhance the growth of the prostate cancer therapeutics market in the forecast period of 2020-2027. On the other hand, limited number of players, increasing pharmaceutical expenditure will further create new opportunities for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Increasing cost of the treatment and adverse impact of treatment along with less success rate will acts as a restraint factor for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Competitive Landscape and Prostate Cancer Therapeutics Market Share Analysis

Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to prostate cancer therapeutics market.

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-prostate-cancer-therapeutics-market

Prostate Cancer Therapeutics Market Country Level Analysis

Prostate cancer therapeutics market is analysed and market size insights and trends are provided by country, drug class and distribution channel as referenced above.

The countries covered in the prostate cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Kuwait, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Peru, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prostate cancer therapeutics market due to increasing occurrence of prostate cancer and high mortality rate along with rising investment in research and development of advanced solutions while Asia-Pacific will witness a growth in forecast period of 2020-2027 because of increasing awareness among people regarding tumours and improvement in healthcare infrastructure in this regions.

The country section of the prostate cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Major Market Drivers and Restraints:

Reasons to Purchase this Report

Customization of the Report

Read More @ https://www.databridgemarketresearch.com/reports/global-prostate-cancer-therapeutics-market

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Prostate Cancer Therapeutics Market with Rising Demand & Huge Application Potential from Industry by 2026 - 3rd Watch News

Data Bridge Market Research has recently added a concise research on the Prostate Cancer Therapeutics Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated. As per study key players of this market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson

Prostate cancer therapeutics marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to reach a market value of USD 18.71 billion by 2027 while growing at a CAGR of 7.70% in the above-mentioned forecast period. Prostate cancer therapeutics market is growing due to factor such as increasing cases of prostate cancer and cardiovascular diseases.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific, Brazil, Peru, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Kuwait, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Major Market Competitors/Players:Global Prostate Cancer Therapeutics Market

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Increasing awareness among people regarding prostate cancer along with technological advancement in screening and diagnostic tests, rising preferences of healthy living will increased geriatric population will enhance the growth of the prostate cancer therapeutics market in the forecast period of 2020-2027. On the other hand, limited number of players, increasing pharmaceutical expenditure will further create new opportunities for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Increasing cost of the treatment and adverse impact of treatment along with less success rate will acts as a restraint factor for the growth of prostate cancer therapeutics market in the above mentioned forecast period.

Competitive Landscape and Prostate Cancer Therapeutics Market Share Analysis

Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to prostate cancer therapeutics market.

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Grab Your Report at an Impressive 30% Discount! Please click Here @

https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-prostate-cancer-therapeutics-market

Prostate Cancer Therapeutics Market Country Level Analysis

Prostate cancer therapeutics market is analysed and market size insights and trends are provided by country, drug class and distribution channel as referenced above.

The countries covered in the prostate cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Kuwait, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Peru, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prostate cancer therapeutics market due to increasing occurrence of prostate cancer and high mortality rate along with rising investment in research and development of advanced solutions while Asia-Pacific will witness a growth in forecast period of 2020-2027 because of increasing awareness among people regarding tumours and improvement in healthcare infrastructure in this regions.

The country section of the prostate cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Major Market Drivers and Restraints:

Reasons to Purchase this Report

Customization of the Report

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read more:
COVID-19 UPDATE: Prostate Cancer Therapeutics Market Increase In Research & Development In Oncology Therapeutic Area with Study Objectives,...

Global Prostate Cancer Therapeutics Market report covers many business strategies such as new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to amplify their footprints in the market. According to this report, the global market is anticipated to see a relatively higher growth rate during the forecast period. The market drivers and restraints have been explained in this industry report using SWOT analysis. The market share of major competitors on global level is also studied in the Global Prostate Cancer Therapeutics Market report where key areas such as Europe, North America, Asia Pacific and South America are covered in this market research report.

The market research data included in this Global Prostate Cancer Therapeutics Market report is analysed and forecasted using market statistical and coherent models. The key research methodology utilized here by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. This global market report additionally encompasses predictions utilizing a practical arrangement of suspicions and techniques. A lot of hard work has been put together and no stone is left unturned while generating this market research report. Global Prostate Cancer Therapeutics Market is a proficient and comprehensive report that focuses on primary and secondary market drivers, market share, leading segments and geographical analysis.

Global Prostate Cancer Therapeutics Market is expected to growing at a CAGR of 12.5% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Download Free PDF Sample Copy of[emailprotected]https://databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-therapeutics-market

Global Prostate Cancer Therapeutics Market,By Drug Type (Hormonal Therapy, Luteinizing Hormone-Releasing Hormone (LHRH) Agonist, Anti-Androgens, Immunotherapy, Targeted Therapy, Chemotherapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Major Market Competitors/Players:

Some of the major players operating in the global prostate cancer therapeutics market are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inc, Johnson & Johnson, IPSEN, Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) , Dendreon Corporation, Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others.

Market Definition:Global Prostate Cancer Therapeutics Market

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease. According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer. The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

Major Market Drivers and Restraints:

Market Segmentation:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is segmented based on drug type, distribution channel and geographical segments.

On the basis of drug type, the market is classified into hormonal therapy, luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgens, immunotherapy, targeted therapy, and chemotherapy

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on geography, the global prostate cancer therapeutics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Key Developments in the Market:

Competitive Analysis:Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of prostate cancer therapeutics market for global, Europe, North America, Asia Pacific and South America.

Reasons to Purchase this Report

Order a Copy of This ResearchReport @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-prostate-cancer-therapeutics-market

Customization of the Report

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read this article:
Global Prostate Cancer Therapeutics Market Future Demand (COVID 19 Impact Analysis) & Growth Analysis with Forecast up to 2027 - 3rd Watch News

Data Bridge Market Research has recently added a concise research on the Clinical Laboratory Services Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated.

Clinical laboratory services marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2020 to 2027 and expected to reach USD 217,941.33 million by 2027 from USD 134,692.52 million in 2019. Rising demand for early and accurate disease diagnosis is the factors for the market growth.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-clinical-laboratory-services-market&captain

Clinical laboratory services is playing significant role to enable doctors to make appropriate clinical and diagnostic decisions across various levels of health care services. Increasing demand for diagnostic tests is augmenting the market growth as they are used for clinical diagnoses tests.

The major players covered in the report are:-

Mayo Foundation for Medical Education and Research (MFMER), Laboratory Corporation of America Holding, Quest Diagnostics Incorporated, Spectra Laboratories (A Subsidiary of Fresenius Medical Care AG & Co. KGaA), DaVita Inc., Eurofins Scientific, UNILABS, SYNLAB International GmbH, MIRACA HOLDINGS Inc., Sonic Healthcare, ACM Global Laboratories, amedes Group, LifeLabs, Alere (A Subsidiary of Abbott), Charles River, Siemens Healthineers AG, BioReference Laboratories, Inc., NeoGenomics Laboratories, Inc., KingMed Diagnostics, Genomic Health, among other players domestic and global. Clinical laboratory services market share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many business expansion and developments are also initiated by the companies worldwide which are also accelerating the growth of global clinical laboratory services market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for Clinical Laboratory Services through expanded model range.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-clinical-laboratory-services-market?utm_source=news&utm_campaign=Captain

Global Clinical Laboratory Services Market By Specialty (Clinical Chemistry Testing, Hematology Testing, Microbiology Testing, Immunology Testing, Drugs of Abuse Testing, Cytology Testing, Genetic Testing), Provider (Hospital-Based Laboratories, Independent & Reference Laboratories, Nursing and Physician Office-Based Laboratories), Application (Bioanalytical & Lab Chemistry Services, Drug Development Related Services, Drug Discovery Related Services, Toxicology Testing Services, Cell & Gene Therapy Related Services, Preclinical & Clinical Trial Related Services, Other Clinical Laboratory Services), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Market Trends and Forecast to 2027

Rising demand of clinical laboratory services across the world is one of the prominent factors for increasing demand of clinical chemistry testing. For instance, yearly in the U.K., the usually citizen has 14 tests completed by a laboratory specialist. However in the U.S., laboratory testing is the only highest-volume medical activity and approximately 13,000 million tests are performed per year. Hence, this factor has led the patients to shift towards clinical chemistry testing because it offers a wide range of tests which are performed in the clinical laboratory testing. In the current scenario the technological advancements boost the patients reach to laboratory testing, which is becoming gradually more precise and affordable. For instance, point-of-care testing (POCT) is regularly applied in hospitals and other healthcare practices, so the patients not need to travel to the clinical laboratories for testing. The increasing use of point-of-care testing has reduced demand tests which are conventionally executed at industry laboratories.

Rising demand of early and accurate disease diagnosis across the globe is one of the prominent factors for an upsurge demand of clinical laboratory services. For instance, in 2018, World Health Organization projected that projected that an estimated 1.8 million new cases and almost 861,000 deaths occur due to colorectal cancer (CRC). This factor has increased the number of clinical laboratories around the globe as Delays in accessing cancer care are very common in the late-stage presentation, especially in lower vulnerable populations and resource settings.

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-clinical-laboratory-services-market&captain

Table of Contents-Snapshot Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

Country Level Analysis, By Provider

North America dominates the clinical laboratory services market as the U.S. is leader in clinical laboratory services. In North America due to better advancement in products and services, this region is dominating the clinical laboratory services. North America accounts higher healthcare expenditure, especially in U.S. Asia-Pacific is growing with the highest CAGR due to increase in medical tourism as well as increase in population. Numbers of companies in emerging countries are increasing due to increase in demand for disease diagnosis in clinics, hospitals and other areas. Additionally, the increasing number of healthcare expenditure and increasing number of hospitals and clinical diagnostic laboratories in China and India upsurge demand of clinical laboratory services. The Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Read More @ https://www.databridgemarketresearch.com/reports/global-clinical-laboratory-services-market?utm_source=news&utm_campaign=Captain

Huge Investment by laboratory for Clinical Laboratory Services and New Technology Penetration

Global clinical laboratory services market also provides you with detailed market analysis for every country growth in life science industry with clinical laboratory services demand impact of technological development in laboratory services and changes in regulatory scenarios with their support for the clinical laboratory services market. The data is available for historic period 2010 to 2018.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Clinical Laboratory Services Market Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2026 - 3rd Watch News

The Global Biopreservation market report presents market dynamics focusing on all the important factors market movements depend on. It includes current market trends with a record from historic year and prediction of the forecast period. This report is a comprehensive market analysis of the Biopreservation market done on a basis of regional and global level. Important market analysis aspects covered in this report are market trends, revenue growth patterns market shares and demand and supply along with business distribution

Request For Sample Biopreservation Market[emailprotected]https://www.adroitmarketresearch.com/contacts/request-sample/645

Bio-banking is further divided into veterinary IVF, human sperm and human eggs whereas regenerative medicine is sub-divided into gene therapy, cell therapy and more. On the basis of product outlook, market is divided into laboratory information management system, media and equipment.

Biopreservation is the increase in the shelf life and developed safety of foods, using the controlled or natural antimicrobial or microbiota compounds. It is the ecological and harmful method to deal with food preservation problem and is getting the attention in the current years. Growth in the demand for the developed methods of preservation and is continuously increasing the spending on healthcare is expected to boost the biopreservation market.

Pharmaceutical companies, biotechnology firms and hospitals are gradually accepting the systems for the in-house storage of the samples and is projected to offer a substantial growth to the global biopreservation market. Increasing the investments in the R&D activities by the research communities and companies are motivated to develop the capabilities of the product is increasing the biopreservation market with large potential.

Make an enquire Before Buying This Report @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/645

Developments in the technology like virtual bio-banks are expected to experience a substantial increase in the application, results in the biopreservation market growth. Moreover, rise in the preference of maintaining the repositories of biological specimen in the regenerative medicine and organ transplantation has promoted the biopreservation industry. With the help of initiatives by government like International Society of Biological and Environmental Repositories to augment the standards of preservation, practices and bio-banking is increasing the possibility for the growth of biopreservation market during the forecast period.

Rise in the expenditure for healthcare is expected to develop the healthcare quality and developed products involve the facilities of biopreservation, by widening the growth of biopreservation market. Moreover, gene banks, bio-banks and hospitals are the substantial consumers for biopreservation industry are influencing the manufacturers to produce the technologically developed products of biopreservation to increase the outcomes of patient and enhance the biopreservation market in the coming future.

With the help of several initiatives by government in healthcare are providing the grants, contracts and funds for research results in offering the growth to R&D activities set by several companies. This results in increasing the opportunity for implementing the developed services of bio-preservation, is projected to boost the growth of biopreservation market over the forecast period. Growth in the investments of R&D by research communities and companies to expand their effective products, services and capabilities is anticipated to increase the growth of biopreservation market. For example, formation of Cooperative Human Tissue Network are addressing the measurement of bio-banking, illustrates the continuous efforts by the community of research.

Get More Information About This Report With[emailprotected]https://www.adroitmarketresearch.com/industry-reports/biopreservation-market

Geographically, regions involved in the development of biopreservation market size are Europe, North America, Latin America, Asia Pacific and Middle East & Africa. U.S biopreservation market is dominating the North America and is propelled to increase the biopreservation industry in the coming years. Asia Pacific is estimated to hold the largest biopreservation market share over the forecast period.

Key players involved in the global biopreservation market are LabVantage Solutions, Thermo-Fischer Scientific, Custom Biogenic Systems, Biomatrica, Qiagen and more.

Key Segments in the Global Biopreservation Market are-

By Cell Provider Outlook, market is segmented into:

By Application, market is segmented into:

By Product Outlook, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Biopreservation Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

See original here:
Biopreservation Market Analysis 2019-2025 Emerging Trends, Growth Drivers, Challengers, Services, Competitive Landscape and Regional Outlook &...

Japanese pharma and biotech friend Takeda is set to spend nearly $1 billion in backloaded payments for a deal with early-stage startup Carmine Therapeutics.

The pair will target rare diseases using gene therapies out of the biotechs red blood cell extracellular vesicles (RBCEVs) platform, which it calls Regent and was first published in Nature back in 2018 (with the startup officially launching a year later).

An initial focus is non-viral gene therapies rather than the traditional path of adeno-associated virus (AAV)-based gene therapies that can lead to unwanted side effects.

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

The biotech said its RBCEV-based gene therapy has the potential for repeat dosing, a significantly larger transgene payload capacity in excess of 11KB, and enhanced bio-distribution in selected tissues through RBCEV surface modification.

The deal could be worth as much as $900 million, with Takeda leading Carmine's convertible note seed plus funding round by extending a $5 million convertible loan to the biotech. Theres an upfront payment and extra research funding cash, though details of dollar amounts here were not given.

Takeda nabs an option to license the programs following the completion of preclinical proof of concept studies; from here, it would be responsible for clinical development and sales.

Carmine Therapeutics was founded last year by Esco Ventures X, a life science fund, professor Harvey Lodish of the Whitehead Institute at MIT and Singaporean professors Minh Le and Jiahai Shi.

Lodish was a founding member of several big biotechs, including Genzyme (which was snapped up by Sanofi).

XQ Lin, founding CEO of Carmine Therapeutics and managing partner of Esco Ventures, said: We are pleased to enter this collaboration with Takeda, a recognized global leader in rare disease therapies, slightly more than a year since Carmine was created and incubated by Esco Ventures X. This provides Carmine with significant funding to further develop our REGENT(TM) platform, and advance our wholly-owned programs.

This also marks another, albeit very early venture into gene therapies for Takeda. In April, German CRO-biotech hybrid Evotec allied with Takeda to expand into gene therapy research. The move saw Evotec establish a 20-person team in Austria, the focal point of Takedas gene therapy operation, and sign up to work on programs for its Japanese partner.

Takeda acquired a gene therapy center in Orth an der Donau, Austria, through its purchase of Shire, which picked up the site two years earlier in its takeover of Baxalta. Throughout the series of changes in ownership, which began when Baxter spun out Baxalta in 2014, a team at the site has worked on gene therapies.

At Takeda, we're expanding our foundation in gene therapy by establishing a network of innovative partners like Carmine Therapeutics who are pursuing non-viral vector approaches that could leapfrog today's technology, added Takeda's rare disease drug discovery unit head Madhu Natarajan.

Developing alternative gene therapy delivery vehicles like the REGENT platform that could address the challenges of AAV gene therapy is critical to one day delivering next-generation cures for rare diseases.

Excerpt from:
Takeda pens $900M biobucks pact with Carmine for non-viral gene therapy work - FierceBiotech

PARIS--(BUSINESS WIRE)-- Regulatory News:

Lysogene (Paris:LYS)(FR0013233475 LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the company has entered into a collaborative research agreement with Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science.

The agreement involves collaboration between Lysogene and the lab of Prof. Anthony Futerman at the Weizmann Institute of Science, with the aim of developing a novel AAV gene therapy approach for neuronopathic Gaucher disease, Parkinson disease, and other diseases associated with mutations of the GBA1 gene. Under the terms of the agreement, Lysogene will provide expertise in AAV vector design and production, while the lab of Prof. Futerman will provide glucocerebrosidase variants with enhanced biological properties and conduct biological proof and concept studies. Lysogene has an exclusive option to license the program.

Ralph Laufer, Chief Scientific Officer at Lysogene said: We are thrilled to start this research collaboration with Prof. Futerman, a leading expert in the field of sphingolipid biology. The Weizmann Institute is one of the world's leading multidisciplinary research institutes, and the source of numerous groundbreaking medical discoveries and technological applications. Lysogene is developing gene therapy approaches for monogenic neurological disorders, including neuronopathic lysosomal storage diseases. This collaboration is a perfect fit with Lysogenes strategy, providing the opportunity to develop a novel therapy for a rare lysosomal disease, with the potential to expand into neurological diseases with much larger patient populations, such as Parkinson.

About Lysogene

Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1/3 clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner on a gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism. http://www.lysogene.com.

Forward Looking Statement

This press release may contain certain forward-looking statements, forecasts and estimates with respect to Lysogenes clinical trials, clinical trial data releases, clinical development plans, anticipated future activities and cash runway of Lysogene. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Companys control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as target, believe, expect, aim, intend, may, anticipate, estimate, plan, objective, project, will, can have, likely, should, would, could and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Companys control that could cause the Companys actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Companys regulatory filings with the French Autorit des Marchs Financiers, including in the 2019 universal registration document, registered with the French Markets Authorities on April 30, 2020, under number D.20-0427, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005931/en/

Visit link:
Lysogene Announces a Research Collaboration With the Weizmann Institute of Science - BioSpace

The Global Cell and Gene Therapy Market Market Research Report 2020 published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.

The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Global Cell and Gene Therapy Market market over the forecast period (2019-2029).

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Global Cell and Gene Therapy Market market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

The facts and data are represented in the Global Cell and Gene Therapy Market report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4053

The research report also focuses on global major leading industry players of Global Cell and Gene Therapy Market market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Global Cell and Gene Therapy MarketMarket Key Companies:

The predictions mentioned in the Global Cell and Gene Therapy Market market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Segmentation Overview:

Global Cell and Gene Therapy Market, By-Products:

Global Cell and Gene Therapy Market, By Distribution Channel Type:

Global Cell and Gene Therapy Market, By End-Users:

The report provides an in-depth analysis of the Global Cell and Gene Therapy Market market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/4053

Key Questions Answered in Report:

Stakeholders Benefit:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-and-Gene-Therapy-4053

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

View Similar Report-

Surgical Kits Market: Opportunities Forecast and Value Chain 2020-2030

Go here to read the rest:
Global Cell and Gene Therapy Market Market: Revenue Growth and Applications Insights - Cole of Duty

The Global Gene Therapy Technologies Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost, and revenue during the forecast period from 2020 to 2027. The report provides a full assessment. Gene Therapy Technologies market with future trends, current growth factors, meticulous opinions, facts, historical data and statistically supported and industry-validated market data.

This Gene Therapy Technologies market research provides a clear explanation of how this market will impress growth during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

To Learn More About This Report, Request a Sample Copy:https://www.worldwidemarketreports.com/sample/116778* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Bluebird bio, Adaptimmune, GlaxoSmithKline, Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, OncoGenex Pharmaceuticals, Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology are some of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

Key players in the Gene Therapy Technologies market were identified through a second survey, and their market share was determined through a primary and second survey. All measurement sharing, splitting, and analysis were solved using a secondary source and a validated primary source. The Gene Therapy Technologies market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure, and when used together, how key players can meet market coverage, offered characteristics, and customer needs It helps to understand.

The report also makes some important suggestions for new Gene Therapy Technologies market projects before evaluating their feasibility. Overall, this report covers Gene Therapy Technologies market Sales, Price, Sales, Gross Profit, Historical Growth,and Future Prospects. It provides facts related to the widespread merger, acquisition, partnership, and joint venture activities on the market.

This report includes market size estimates of value (million US $) and trading volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Gene Therapy Technologies market, estimating the size of various other subordinate markets in the overall market. All ratio sharing, splitting, and analysis were determined using the secondary source and the identified primary source.

What Gene Therapy Technologies Market report offers:

Remarkable Attributes of Gene Therapy Technologies Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Read more from the original source:
Gene Therapy Technologies Market 2020 by Latest Innovations, Emerging Technology and Top Key Players: Bluebird bio, Adaptimmune, GlaxoSmithKline -...

5pm on June 26, 2020 - Kawasaki/Japan: The Innovation Center of NanoMedicine (iCONM), the National Institute for Quantum Science and Technology (QST), and the University of Tokyo jointly announced that a reagent for the selective and safe coating of the liver sinusoidal walls to control the clearance of gene therapy drugs was successfully developed. The contents of this research will be published in Science Advances by the American Association for the Advancement of Science (AAAS) at 2:00 pm on June 26, east coast of the United States (Japan standard time: 3:00 am on 27th): A. Dirisala, S. Uchida, K. Toh, J. Li, S. Osawa, T. A. Tockary, X. Liu, S. Abbasi, K. Hayashi, Y. Mochida, S. Fukushima, H. Kinoh, K. Osada, Kazunori Kataoka, "Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines".

Recently, gene therapies have been successively approved in Europe, US, and Japan, and are expected to provide novel therapeutic options for cancer, chronic diseases, acquired and inherited genetic disorders. Whilst this is promising, in reality, when gene therapy drugs are systemically administered to living organisms, they are rapidly eliminated and metabolized in the liver, thus impeding the delivery of a sufficient amount to the target organs and raising the toxicity concerns. This elimination by the liver is caused by the adsorption of the gene therapy drugs to the vascular wall of the liver sinusoid, which is an intrahepatic capillary. To overcome this issue, we conceived to selectively coat the liver sinusoidal wall using polyethylene glycol (PEG). However, a long-term coating may impair the normal physiological functions of the liver, and therefore the coating should be transient. In addition, coating needs to be selective for liver sinusoids, as coating the blood vessels throughout the body would not only cause adverse effects but also decrease the delivery amount of gene therapy drugs to target organs. Towards this end, we have developed a coating agent with two-armed PEG conjugated to positively charged oligolysine, which demonstrated the selective coating on the liver sinusoidal wall, the first-of-its-kind strategy in the world. Interestingly, the coating with two-armed PEG was excreted into bile within 6 hours after binding to sinusoidal walls, while the coating with single chain of linear PEG bound to oligolysine persisted in the walls for a long time. In this way, the precise molecular design was necessary to achieve a transient coating.

This coating was subsequently applied to boost the delivery efficacy of gene therapy drugs. Adeno-associated virus (AAV) is widely used for viral gene therapy drugs, and its serotype 8 (AAV8) targets myocardium and skeletal muscles. When AAV8 was administered after prior coating of two-armed PEG to the liver sinusoidal wall, the transfer of AAV8 to the liver was suppressed, and as a result, the gene transfer efficiency into the myocardium and skeletal muscles was improved by 2 to 4 times. This approach is promising for the treatment of muscular dystrophy. In addition, we expanded the use of our strategy to virus-free gene delivery systems, which allows more economically attractive and safe gene therapy. We have been working on non-viral gene therapy for malignant tumors using plasmid DNA-equipped smart nanomachine for over 10 years. When the coating agent was used for this system, the adsorption of nanomachines to the sinusoidal wall was suppressed, resulting in an approximately 10-fold improvement in DNA transfer efficiency to colon cancer. As described above, we have succeeded in boosting the activity of gene therapy drugs while ensuring safety by using the coating agent developed this time.

The above findings are summarized as follows:

- The coating agent with two-armed PEG selectively coated the liver sinusoid wall for several hours and was then excreted in the bile.

- The coating agent with single chain of linear PEG is not excreted in bile and coated the liver sinusoidal wall for more than 9 hours, which raises a safety concern.

- The coating agent with two-armed PEG had selectivity for the liver sinusoid wall, without coating the blood vessels in the connective tissues.

- The coating agent improved the gene transfer efficacy to the myocardium and skeletal muscles using the AAV vector by 2 to 4 times, and the gene transfer efficiency to colorectal cancer using DNA-loaded smart nanomachines by 10 times.

- As a result, our approach is expected to allow for improving the effect of gene therapy drugs and reducing their dose needed to obtain therapeutic outcome, which will lead to the reduction of medical cost and adverse event opportunities.

Read the original post:
Development of safe liver sinusoid coating agents to increase the efficacy of gene therapy - Science Codex